Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.65 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | MARK3 | P27448 | 1/20 | 0.37 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.37 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3445913 | 0.95 | BUB1 (0.60) | BUB1GPR119PIM1MARK3MAP4K2 | |
| SCHEMBL3445914 | 0.86 | BUB1 (0.51) | BUB1GPR119PIM1MARK3MAP4K2 | |
| SCHEMBL24852180 | 0.82 | BUB1 (0.54) | BUB1GPR119PIM1PIM2ELANE | |
| SCHEMBL17372467 | 0.79 | BUB1 (1.00) | BUB1BCHEHSP90AA1HSP90AB1ACHE | |
| SCHEMBL20780061 | 0.79 | BUB1 (0.50) | BUB1GPR119PIM1MARK3MAP4K2 | |
| SCHEMBL13477016 | 0.78 | HPGD (0.43) | BUB1ELANEPLK1CSNK2A1PLK3 | |
| SCHEMBL17498059 | 0.78 | BUB1 (0.47) | BUB1GPR119PIM1MARK3MAP4K2 | |
| SCHEMBL13397249 | 0.74 | CSNK2A1 (0.42) | BUB1ELANEPLK1CSNK2A1PLK3 | |
| SCHEMBL2208073 | 0.74 | ELANE (0.62) | BUB1GPR119ELANEPLK1CSNK2A1 | |
| SCHEMBL3445222 | 0.74 | BUB1 (0.40) | BUB1GPR119PIM1PIM2ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630759-B1 | COMPOUNDS USEFUL AS ION CHANNEL INHIBITORS FOR THE TREATMENT OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2024-05-01 | — | — | EP | disclosed |
| US-11932638-B2 | Ion channel inhibitor compounds for cancer treatment | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE (FR) | 2024-03-19 | — | — | US | disclosed |
| US-20240002370-A1 | PYRROLE-TYPE COMPOUNDS AND USES THEREOF FOR TREATING VIRAL INFECTIONS | ENYO PHARMA (FR) | 2024-01-04 | — | — | US | disclosed |
| US-20210009581-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CHU NANTES (FR) | 2021-01-14 | — | — | US | disclosed |
| EP-3630759-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | Centre National De La Recherche Scientifique (FR) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215557-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-11-29 | — | — | WO | disclosed |
| EP-3138843-A1 | ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR | Medshine Discovery Inc. (CN) | 2017-03-08 | — | — | EP | disclosed |
| US-20170037050-A1 | ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2017-02-09 | — | — | US | disclosed |
| US-20170037050-A1 | ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2017-02-09 | — | — | US | disclosed |
| WO-2015165341-A1 | ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR | 南京明德新药研发股份有限公司 | 2015-11-05 | — | — | WO | disclosed |
| US-20120010263-A1 | ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY | NOVARTIS AG (CH) | 2012-01-12 | — | — | US | disclosed |
| US-7816536-B2 | enantioselective functionalization at the less reactive 4-position; alkenylation of the 4-(leaving group)-6,7-dihydro ring with an electron-withdrawing vinyldiazo compound using a a dirhodium catalyst; drug intermediate | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816536-B2 | enantioselective functionalization at the less reactive 4-position; alkenylation of the 4-(leaving group)-6,7-dihydro ring with an electron-withdrawing vinyldiazo compound using a a dirhodium catalyst; drug intermediate | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-10-19 | — | — | US | disclosed |
| US-20080146647-A1 | ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY | NOVARTIS AG (CH) | 2008-06-19 | — | — | US | disclosed |
| US-7348353-B2 | Acetylene derivatives having mGluR 5 antagonistic activity | NOVARTIS AG (CH) | 2008-03-25 | — | — | US | disclosed |
| US-20070004787-A1 | enantioselective functionalization at the less reactive 4-position; alkenylation of the 4-(leaving group)-6,7-dihydro ring with an electron-withdrawing vinyldiazo compound using a a dirhodium catalyst; drug intermediate | NATIONAL SCIENCE FOUNDATION | 2007-01-04 | — | — | US | disclosed |
| US-20070004787-A1 | enantioselective functionalization at the less reactive 4-position; alkenylation of the 4-(leaving group)-6,7-dihydro ring with an electron-withdrawing vinyldiazo compound using a a dirhodium catalyst; drug intermediate | NATIONAL SCIENCE FOUNDATION | 2007-01-04 | — | — | US | disclosed |
| WO-2006135804-A1 | 4-SUBSTITUTED AND 7-SUBSTITUTED INDOLES, BENZOFURANS, BENZOTHIOPHENES, BENZIMIDAZOLES, BENZOXAZOLES, AND BENZOTHIAZOLES AND METHODS FOR MAKING SAME | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-12-21 | — | — | WO | disclosed |
| EP-1453512-B1 | ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY | NOVARTIS AG (CH) | 2006-05-31 | — | — | EP | disclosed |
| US-20050065191-A1 | Acetylene derivatives having mglur 5 antagonistic activity | NOVARTIS AG (CH) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002370-A1 | PYRROLE-TYPE COMPOUNDS AND USES THEREOF FOR TREATING VIRAL INFECTIONS | PPIE, PYCR1, PIN1 | BUB1 4005/4885GPR119 4028/4885PIM1 672/4885 |
| US-20080146647-A1 | ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY | GRM5, GRIK5, GRM1 | BUB1 4122/4885GPR119 100/4885PIM1 4243/4885 |
| US-20070004787-A1 | enantioselective functionalization at the less reactive 4-position; alkenylation of the 4-(leaving group)-6,7-dihydro ring with an electron-withdrawing vinyldiazo compound using a a dirhodium catalyst; drug intermediate | CYP3A4, CYP2D6, CYP3A7 | BUB1 4036/4885GPR119 3298/4885PIM1 275/4885 |
| US-20050065191-A1 | Acetylene derivatives having mglur 5 antagonistic activity | GRM5, GRM1, GRM2 | BUB1 3932/4885GPR119 137/4885PIM1 4118/4885 |
| US-11932638-B2 | Ion channel inhibitor compounds for cancer treatment | CACNA1E, KCNA1, KCNT1 | BUB1 1342/4885GPR119 1386/4885PIM1 2076/4885 |
| US-20120010263-A1 | ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY | GRM5, GRIK5, GRM1 | BUB1 4122/4885GPR119 100/4885PIM1 4243/4885 |
| US-20170037050-A1 | ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR | ROCK1, ROCK2, CIT | BUB1 1106/4885GPR119 2365/4885PIM1 414/4885 |
| US-20210009581-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CACNA1E, KCNA1, KCNT1 | BUB1 1342/4885GPR119 1386/4885PIM1 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.